450 related articles for article (PubMed ID: 23799045)
1. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models.
Shi S; Wang R; Chen Y; Song H; Chen L; Huang G
PLoS One; 2013; 8(6):e65757. PubMed ID: 23799045
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models.
Tao L; Huang G; Shi S; Chen L
Med Oncol; 2014 Jan; 31(1):777. PubMed ID: 24271420
[TBL] [Abstract][Full Text] [Related]
3. Synergistic antitumor effect of combining metronomic chemotherapy with adoptive cell immunotherapy in nude mice.
Shi S; Tao L; Song H; Chen L; Huang G
APMIS; 2014 May; 122(5):380-91. PubMed ID: 24628659
[TBL] [Abstract][Full Text] [Related]
4. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
5. Influence of the number and interval of treatment cycles on cytokine-induced killer cells and their adjuvant therapeutic effects in advanced non-small-cell lung cancer (NSCLC).
Gu Y; Lv H; Zhao J; Li Q; Mu G; Li J; Wuyang J; Lou G; Wang R; Zhang Y; Huang X
Int Immunopharmacol; 2017 Sep; 50():263-269. PubMed ID: 28711032
[TBL] [Abstract][Full Text] [Related]
6. The CIK cells stimulated with combination of IL-2 and IL-15 provide an improved cytotoxic capacity against human lung adenocarcinoma.
Wei C; Wang W; Pang W; Meng M; Jiang L; Xue S; Xie Y; Li R; Hou Z
Tumour Biol; 2014 Mar; 35(3):1997-2007. PubMed ID: 24104501
[TBL] [Abstract][Full Text] [Related]
7. Adoptive immunotherapy of cytokine-induced killer cell therapy in the treatment of non-small cell lung cancer.
Wang M; Cao JX; Pan JH; Liu YS; Xu BL; Li D; Zhang XY; Li JL; Liu JL; Wang HB; Wang ZX
PLoS One; 2014; 9(11):e112662. PubMed ID: 25412106
[TBL] [Abstract][Full Text] [Related]
8. Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS).
Zhao Y; Qiao G; Wang X; Song Y; Zhou X; Jiang N; Zhou L; Huang H; Zhao J; Morse MA; Hobeika A; Ren J; Lyerly HK
Clin Transl Oncol; 2019 Jun; 21(6):721-728. PubMed ID: 30374838
[TBL] [Abstract][Full Text] [Related]
9. Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients.
Yang L; Ren B; Li H; Yu J; Cao S; Hao X; Ren X
Cancer Immunol Immunother; 2013 Jan; 62(1):65-73. PubMed ID: 22744010
[TBL] [Abstract][Full Text] [Related]
10. Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers.
Zuo S; Wen Y; Panha H; Dai G; Wang L; Ren X; Fu K
Mol Immunol; 2017 May; 85():293-304. PubMed ID: 28360017
[TBL] [Abstract][Full Text] [Related]
11. Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients.
Zhang L; Wang J; Wei F; Wang K; Sun Q; Yang F; Jin H; Zheng Y; Zhao H; Wang L; Yu W; Zhang X; An Y; Yang L; Zhang X; Ren X
Oncotarget; 2016 Jul; 7(28):43604-43615. PubMed ID: 27283895
[TBL] [Abstract][Full Text] [Related]
12. In vivo distribution and antitumor effect of infused immune cells in a gastric cancer model.
Du X; Jin R; Ning N; Li L; Wang Q; Liang W; Liu J; Xu Y
Oncol Rep; 2012 Nov; 28(5):1743-9. PubMed ID: 22948809
[TBL] [Abstract][Full Text] [Related]
13. Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis.
Jiang WG; Lu XA; Shang BY; Fu Y; Zhang SH; Zhou D; Li L; Li Y; Luo Y; Zhen YS
BMC Cancer; 2013 Oct; 13():479. PubMed ID: 24128285
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cell immunotherapy combined with cytokine-induced killer cells promotes skewing toward Th2 cytokine profile in patients with metastatic non-small cell lung cancer.
Zhao P; Bu X; Wei X; Sun W; Xie X; Li C; Guo Q; Zhu D; Wei X; Gao D
Int Immunopharmacol; 2015 Apr; 25(2):450-6. PubMed ID: 25698555
[TBL] [Abstract][Full Text] [Related]
15. Synergistic effect of cytokine-induced killer cell with valproate inhibits growth of hepatocellular carcinoma cell in a mouse model.
Lee DH; Nam JY; Chang Y; Cho H; Kang SH; Cho YY; Cho E; Lee JH; Yu SJ; Kim YJ; Yoon JH
Cancer Biol Ther; 2017 Jan; 18(1):67-75. PubMed ID: 28055304
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy with sequential cytokine-induced killer (CIK) cells in stage IB non-small cell lung cancer.
Li DP; Li W; Feng J; Chen K; Tao M
Oncol Res; 2015; 22(2):67-74. PubMed ID: 25706393
[TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
[TBL] [Abstract][Full Text] [Related]
18. CIK cell-based delivery of recombinant adenovirus KGHV500 carrying the anti-p21Ras scFv gene enhances the anti-tumor effect and safety in lung cancer.
Lin XR; Zhou XL; Feng Q; Pan XY; Song SL; Fang H; Lei J; Yang JL
J Cancer Res Clin Oncol; 2019 May; 145(5):1123-1132. PubMed ID: 30796510
[TBL] [Abstract][Full Text] [Related]
19. Polysaccharides from Hedyotis diffusa enhance the antitumor activities of cytokine-induced killer cells.
Ma C; Wei Y; Liu Q; Xin Y; Cao G; Wang X; Yang P
Biomed Pharmacother; 2019 Sep; 117():109167. PubMed ID: 31387180
[TBL] [Abstract][Full Text] [Related]
20. Increased cycles of DC/CIK immunotherapy decreases frequency of Tregs in patients with resected NSCLC.
Song H; Liu S; Zhao Z; Sun W; Wei X; Ma X; Zhao P; Gao D
Int Immunopharmacol; 2017 Nov; 52():197-202. PubMed ID: 28941416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
